October 31, 2025
Clozapine in Hospice: What you need to know
Clozapine is a highly effective atypical antipsychotic, but it’s not without drawbacks (Table 1). Historically, patients, prescribers and pharmacies were required to enroll in the Clozapine REMS program due to the drug’s potential to cause agranulocytosis. The REMS program was officially eliminated on June 13th, 2025, though the FDA still recommends that prescribers monitor absolute […]
Read More
August 19, 2025
Considerations for Antiseizure Medication Conversions
Our hospice partners occasionally ask how to convert patients from one antiseizure medication (ASM) to another. These requests are usually driven by cost or formulary considerations, but other common reasons include lack of efficacy, intolerable adverse effects, and problematic drug-drug interactions. Ideally, formulary / cost shouldn’t be the sole basis for rotating to an alternate […]
Read More
